Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a personal coach at home boost energy for cancer patients?

NCT ID NCT03169075

Symptom relief Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendations. The goal is to see if the program improves fatigue, quality of life, and overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supervised home-based physical exercise program
What this could lead to
If effective, this program could offer a practical way to reduce fatigue and improve well-being for people with metastatic cancer on oral targeted therapy.
What could go wrong
The trial is early and the benefits of exercise in this setting are not yet proven. Some patients may find the program difficult to maintain, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

190 people

The number who actually took part.

Started

Jul 2017

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient's ≥18 years old. 2. Patient treated for a metastatic solid tumour within the following 4 cohorts: breast cancer, kidney cancer, lung cancer, and other tumours treated with oral targeted therapies (including melanomas, sarcomas, hepatic sarcomas, and colon cancers). 3. Patients starting first-line oral targeted therapy, with market authorisation. The targeted therapy may be associated with hormonal therapy. 4. Patients may have been treated with immunotherapy. 5. Patients may have received chemotherapy (≤2 lines) for their metastatic disease. 6. Life expectancy of ≥3 months. 7. ECOG performance status ≤2. 8. Patients able to comply with the constraints of the SPEP protocol. 9. Pain under control (VAS ˂3; 0-10 scale). 10. Haemoglobin level ≥9 g/dL. 11. Patient must have signed the informed consent form before any study-related procedures. 12. Patients must have public health insurance coverage. Exclusion Criteria: 1. Patient receiving an injectable targeted therapy. 2. Patient previously treated by more than 2 lines of treatment (previous treatment with cytokines are allowed) 3. Patient to be treated with chemotherapy associated with the oral targeted therapy (hormonal therapy is allowed). 4. Patient with known risk of fracture, symptomatic cardiac insufficiency (NYHA-3), respiratory insufficiency (grade 3), intense pain not controlled with analgesic treatment, and/or neuropathy (grade 3). 5. Patients with a history of cancer in the last 5 years (except basal cell carcinoma adequately treated and in situ cervical cancer treated and cured). 6. Patient treated with corticotherapy (˃1 month) before randomisation at a dose ˃1 mg/kg. 7. Bone metastases with risk of fractures. 8. Geographical, sociological, or psychological reasons that could potentially hampering compliance with the study protocol and follow-up schedule. 9. Patients with a history of non-compliance to medical treatment, reluctance or incapable to conform to the study protocol. 10. Persons deprived of liberty or under guardianship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Home based standardised adapted physical activity programme are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer Fatigue kidney cancer liver sarcoma lung cancer metastatic malignant neoplasm in the colon metastatic melanoma metastatic neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Home based standardised adapted physical activity programme Patients taking oral targeted therapy for metastatic cancer

Contacts and locations

Locations

  • CH Annecy Genevois - site d'Annecy

    Annecy, 74474, France

  • CH Nimes - Institut de Cancérologie du Gard

    Nîmes, 30000, France

  • CH de Cholet

    Cholet, 49300, France

  • CHD Vendée

    La Roche-sur-Yon, 85925, France

  • CHRU de Besançon

    Besançon, 25000, France

  • CHU La Timone

    Marseille, 13000, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14076, France

  • GHMG - Institut Daniel Hollard

    Grenoble, MD Phd, France

  • HIA Begin

    Saint-Mandé, 94160, France

  • Hospices Civils de Lyon - Hôpital Louis Pradel

    Lyon, 69000, France

  • ICO Paul Papin

    Angers, 49000, France

  • ICO RenéGauducheau

    Nantes, 44000, France

  • INSTITUT CURIE - Site René Huguenin St Cloud

    Saint-Cloud, 92000, France

  • Institut Curie Paris

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.